A Phase II Study of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma

Share
Print

Full Title

A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects with Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin

Purpose

The purpose of this study is to assess the safety and effectiveness of the investigational drug rivoceranib in patients with recurrent or metastatic adenoid cystic carcinoma that cannot be cured with surgery or radiation therapy. Rivoceranib stops the formation of new blood vessels that cancer cells need to grow and spread. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or metastatic adenoid cystic carcinoma that cannot be cured with surgery or radiation therapy.
  • At least 4 weeks must pass between the completion of prior treatment (12 weeks since immunotherapy) and receipt of rivoceranib.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alan Ho at 646-608-3774.

Protocol

20-213

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators